WO2000021505A3 - Zusammensetzung für die parenterale applikation von wirkstoffen - Google Patents

Zusammensetzung für die parenterale applikation von wirkstoffen Download PDF

Info

Publication number
WO2000021505A3
WO2000021505A3 PCT/EP1999/007300 EP9907300W WO0021505A3 WO 2000021505 A3 WO2000021505 A3 WO 2000021505A3 EP 9907300 W EP9907300 W EP 9907300W WO 0021505 A3 WO0021505 A3 WO 0021505A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
parenteral administration
active agents
support material
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/007300
Other languages
English (en)
French (fr)
Other versions
WO2000021505A2 (de
Inventor
Juergen Grande
Silke Schuth
Gitte Boehm
Holger Bengs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Research and Technologies GmbH and Co KG
Original Assignee
Aventis Research and Technologies GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Research and Technologies GmbH and Co KG filed Critical Aventis Research and Technologies GmbH and Co KG
Priority to AU61989/99A priority Critical patent/AU6198999A/en
Priority to EP99948917A priority patent/EP1124538A2/de
Priority to JP2000575481A priority patent/JP2002527376A/ja
Priority to CA002346670A priority patent/CA2346670A1/en
Publication of WO2000021505A2 publication Critical patent/WO2000021505A2/de
Publication of WO2000021505A3 publication Critical patent/WO2000021505A3/de
Priority to NO20011670A priority patent/NO20011670L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die vorliegende Erfindung betrifft eine Zusammensetzung für die parenterale Verabreichung von Wirkstoffen, enthaltend ein Trägermaterial und mindestens einen Wirkstoff, wobei das Trägermaterial sphärische Mikropartikel mit einem mittleren Durchmesser von 1 nm bis 100 νm enthält, die ganz oder teilweise aus mindestens einem wasserunlöslichen linearen Polysaccharid, insbesondere einem linearen Polyglucan, bestehen, eine Suspension, die diese Zusammensetzung enthält, sowie deren Verwendung.
PCT/EP1999/007300 1998-10-15 1999-10-02 Zusammensetzung für die parenterale applikation von wirkstoffen Ceased WO2000021505A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU61989/99A AU6198999A (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active agents
EP99948917A EP1124538A2 (de) 1998-10-15 1999-10-02 Zusammensetzung für die parenterale applikation von wirkstoffen
JP2000575481A JP2002527376A (ja) 1998-10-15 1999-10-02 活性物質非経口投与用組成物
CA002346670A CA2346670A1 (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active compounds
NO20011670A NO20011670L (no) 1998-10-15 2001-04-03 Preparat for parenteral administrering av aktive forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1998147593 DE19847593A1 (de) 1998-10-15 1998-10-15 Zusammensetzung für die parenterale Applikation von Wirkstoffen
DE19847593.4 1998-10-15

Publications (2)

Publication Number Publication Date
WO2000021505A2 WO2000021505A2 (de) 2000-04-20
WO2000021505A3 true WO2000021505A3 (de) 2000-09-21

Family

ID=7884587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007300 Ceased WO2000021505A2 (de) 1998-10-15 1999-10-02 Zusammensetzung für die parenterale applikation von wirkstoffen

Country Status (8)

Country Link
EP (1) EP1124538A2 (de)
JP (1) JP2002527376A (de)
AU (1) AU6198999A (de)
CA (1) CA2346670A1 (de)
DE (1) DE19847593A1 (de)
NO (1) NO20011670L (de)
PL (1) PL347770A1 (de)
WO (1) WO2000021505A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022095B4 (de) * 2000-05-08 2005-07-14 Südzucker AG Mannheim/Ochsenfurt Gel aus einem Poly-α-1,4-Glucan und Stärke
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
PT3659437T (pt) 2004-01-23 2022-06-20 Eden Research Plc Métodos para matar nemátodos que compreendem a aplicação de um componente terpeno encapsulado
EP2338332B1 (de) 2004-05-20 2014-02-12 Eden Research Plc Hohles glukan- oder zellenwand-partikel, das eine terpenkomponente verkapselt
WO2008106571A2 (en) 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2328732A1 (fr) * 1975-10-21 1977-05-20 Takeda Chemical Industries Ltd Perles de polysaccharide a base de b-1,3-glucane
EP0053580A2 (de) * 1980-11-29 1982-06-09 Sandoz Ag Arzneimittel
WO1995031553A1 (en) * 1994-05-18 1995-11-23 Institut Für Genbiologische Forschung Berlin Gmbh DNA SEQUENCES CODING FOR ENZYMES CAPABLE OF FACILITATING THE SYNTHESIS OF LINEAR α-1,4 GLUCANS IN PLANTS, FUNGI AND MICROORGANISMS
WO1999011695A1 (de) * 1997-08-28 1999-03-11 Aventis Research & Technologies Gmbh & Co Kg Sphärische lineare polysaccharide enthaltende mikropartikel
WO1999052506A1 (de) * 1998-04-09 1999-10-21 Axiva Gmbh Partikulärer wirkstoffträger für die pulmonale applikation
WO2000012590A1 (de) * 1998-08-28 2000-03-09 Celanese Ventures Gmbh Verfahren zur herstellung von sphärischen mikropartikeln, die ganz oder teilweise aus mindestens einem wasserunlöslichen verzweigungen enthaltenden polyglucan bestehen, sowie mit diesem verfahren erhältliche mikropartikel

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2328732A1 (fr) * 1975-10-21 1977-05-20 Takeda Chemical Industries Ltd Perles de polysaccharide a base de b-1,3-glucane
EP0053580A2 (de) * 1980-11-29 1982-06-09 Sandoz Ag Arzneimittel
WO1995031553A1 (en) * 1994-05-18 1995-11-23 Institut Für Genbiologische Forschung Berlin Gmbh DNA SEQUENCES CODING FOR ENZYMES CAPABLE OF FACILITATING THE SYNTHESIS OF LINEAR α-1,4 GLUCANS IN PLANTS, FUNGI AND MICROORGANISMS
WO1999011695A1 (de) * 1997-08-28 1999-03-11 Aventis Research & Technologies Gmbh & Co Kg Sphärische lineare polysaccharide enthaltende mikropartikel
WO1999052506A1 (de) * 1998-04-09 1999-10-21 Axiva Gmbh Partikulärer wirkstoffträger für die pulmonale applikation
WO2000012590A1 (de) * 1998-08-28 2000-03-09 Celanese Ventures Gmbh Verfahren zur herstellung von sphärischen mikropartikeln, die ganz oder teilweise aus mindestens einem wasserunlöslichen verzweigungen enthaltenden polyglucan bestehen, sowie mit diesem verfahren erhältliche mikropartikel

Also Published As

Publication number Publication date
NO20011670L (no) 2001-06-12
EP1124538A2 (de) 2001-08-22
WO2000021505A2 (de) 2000-04-20
CA2346670A1 (en) 2000-04-20
NO20011670D0 (no) 2001-04-03
DE19847593A1 (de) 2000-04-20
PL347770A1 (en) 2002-04-22
AU6198999A (en) 2000-05-01
JP2002527376A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
EP0864326A3 (de) Mehrphasige wirkstoffhaltige Zubereitungsformen
CA2338358A1 (en) Compounds and compositions for delivering active agents
SI9520106B (sl) Modafinil, ki ima definirano velikost delcev
MY102037A (en) Hydrosols of pharmacologically active agents and their pharmaceutical compositions
EP1944019A3 (de) Proteinstabilisierte pharmakologisch aktive Wirkstoffe, Verfahren zu ihrer Herstellung und Verfahren zu ihrer Verwendung
MY111172A (en) Perfume particles.
WO2002062881A3 (en) Foam including surface-modified nanoparticles
WO2003024396A3 (en) Dry powder medicament formulations
AU1289199A (en) Articles or compositions comprising nanoscale particles; methods of utilizing orproducing such particles
EP1210942A3 (de) Micropartikel
AU7408991A (en) Aqueous cosmetic or dermo-pharmaceutical composition containing, in suspension, hydrated spheroids of a hydrophilic lipidic substance
WO2000021505A3 (de) Zusammensetzung für die parenterale applikation von wirkstoffen
WO1998018435A3 (en) Conditioning shampoo composition
DK0685232T3 (da) Cefiximpræparat
HUP0102086A3 (en) 8-azabicyclo[3.2.1]octane-3-methanamine derivatives and pharmaceutical compositions containing the same
ZA200007633B (en) Pesticide preparations in the form of aqueous suspension.
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
WO2001047474A3 (de) Verwendung von nanoskaligen deodorantien
CA2363156A1 (en) Deodorant compositions
CA2273272A1 (en) Immediate release drug delivery forms
AU3706999A (en) Controlled release tablet produced from linear water-insoluble polysaccharides
EP1044972A4 (de) 5,6,7-TRINOR-4,8-INTER-m-PHENYLEN PGI2 DERIVATE UND SIE ENTHALTENDE MEDIKAMENTE
WO2000037546A3 (de) Expandierte polypropylen-partikel
AU6315300A (en) Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
AU7467994A (en) Novel polysaccharide and radioprotective agent containing the same as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN CZ JP KR NO NZ PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN CZ JP KR NO NZ PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2346670

Country of ref document: CA

Ref document number: 2346670

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 99812073.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 575481

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09834741

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999948917

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 61989/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999948917

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999948917

Country of ref document: EP